All‐cause mortality WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in all‐cause mortality WMD of compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · exacerbations of COPD
Antibiotics showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review
Mortality ‐ not reported · acute asthma exacerbation
The review found no eligible studies for this question.
1 finding from 1 review
Inpatient mortality · exacerbations of COPD
Antibiotics showed no clear difference in all‐cause mortality ‐ inpatients compared with placebo (moderate certainty).
1 finding from 1 review
ICU mortality · exacerbations of COPD
Antibiotics probably leads to lower all‐cause mortality ‐ ICU patients compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults with bronchiectasis
1 finding from 1 review
All‐cause mortality · children with bronchiectasis
1 finding from 1 review
All‐cause mortality · children with bronchiectasis
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · adults with bronchiectasis
1 finding from 1 review
All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review